Eikon Therapeutics, Inc. (NASDAQ:EIKN) Given Consensus Rating of “Hold” by Brokerages

Eikon Therapeutics, Inc. (NASDAQ:EIKN) has earned an average rating of “Hold” from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $25.20.

Several equities research analysts have recently issued reports on EIKN shares. Mizuho started coverage on Eikon Therapeutics in a research report on Monday, March 2nd. They issued an “outperform” rating and a $26.00 price target on the stock. Zacks Research raised Eikon Therapeutics to a “hold” rating in a research report on Friday, February 27th. JPMorgan Chase & Co. started coverage on Eikon Therapeutics in a research report on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price target on the stock. Morgan Stanley started coverage on Eikon Therapeutics in a research report on Monday, March 2nd. They issued an “overweight” rating and a $32.00 price target on the stock. Finally, Wall Street Zen downgraded Eikon Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, April 5th.

Eikon Therapeutics Stock Performance

NASDAQ EIKN opened at $8.77 on Wednesday. Eikon Therapeutics has a 1-year low of $7.90 and a 1-year high of $17.40. The stock has a fifty day moving average of $10.30.

Eikon Therapeutics (NASDAQ:EIKN) last posted its earnings results on Monday, March 30th. The company reported ($26.23) EPS for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.